Cadila Healthcare’s stock jumped 4.76% to Rs 363.30 on the BSE on a plan to raise $100 million from foreign markets. The scrip had touched a high peak of Rs 364.50 and a low of Rs 345.

During the last month, the company’s share price had soared in the range of Rs 320-Rs 335. On 15 June 2007, it climbed from Rs 332.80 on 8 June 2007 to Rs 346.80.

The company's board has sanctioned a plan to issue foreign currency convertible bonds (FCCBs) or such other instruments with green shoe option for this purpose

In Q4 March 2007, Cadila Healthcare had posted a 68.16% increase in its net profit to Rs 37.50 crore as against Rs 22.30 crore in Q4 March 2006. Sales were up 15.64% to Rs 320.10 crore and the net profit climbed up 24.14% to Rs 204.70 crore.

On 12 June 2007, the company got approvals for three products from the US Food & Drug Administration to market Benzonatate Tablets 100 and 200 mili gram (mg), Naproxen Tablets and tentative approval for Amlodipine Besylate Tablets 2.5 mg, 5 mg and 10 mg. The company will market all three drugs through its US subsidiary Zydus Pharmaceuticals (USA) Inc.

The flagship company of Zydus Cadila Group, Cadila Healthcare operates in pharmaceuticals (human formulations, veterinary formulations and bulkdurgs), diagnostics, herbal products, skin care products and OTC products.